FLI1 and gastric cancer: For subgroup analysis, MSI−/EBV− GC patients with FLI1 hypermethylation in plasma samples had a trend of worse 5-year OS rates (33.3% vs. 56.1%, P = 0.104) and a significantly worse 5-year DFS rates (29.2% vs. 53.7%, P = 0.033) than those without FLI1 hypermethylation, which was not observed in MSI+ or EBV+ GC.